Kilpatrick Townsend


Insights: Publications The Fast and the Furious: Article 76 Proceedings in China Proceed with Speed Kilpatrick Townsend MEMO\|Biopharma Industry Blog July 1, 2022 Written by Yifan Mao and April Abele Isaacson Article 76 of the Fourth Amendment to the Chinese Patent Law links regulatory approval of a generic drug and patent protection of the brand-name drug. It establishes a legal framework for resolving drug patent disputes before approval of the generic drug product similar to the Hatch-Waxman Act in the United States. Related People Yifan Mao t 650.324.6311 ymao@ktslaw.com April Abele Isaacson t 415.273.8306 aisaacson@ktslaw.com

Insights: Publications

The Fast and the Furious: Article 76 Proceedings in China Proceed with Speed

Kilpatrick Townsend MEMO|Biopharma Industry Blog

July 1, 2022

Written by Yifan Mao and April Abele Isaacson

Article 76 of the Fourth Amendment to the Chinese Patent Law links regulatory approval of a generic drug and patent protection of the brand-name drug. It establishes a legal framework for resolving drug patent disputes before approval of the generic drug product similar to the Hatch-Waxman Act in the United States.

Related People

Yifan Mao

t 650.324.6311

ymao@ktslaw.com

April Abele Isaacson

t 415.273.8306

aisaacson@ktslaw.com